Armour Thyroid vs Tirosint: Real-World Evidence Comparison

What Are These Two Drugs and How Do They Work?

Armour Thyroid is a natural desiccated thyroid (NDT) extract from porcine (pig) thyroid glands standardized to contain 38 mcg of T4 (levothyroxine) and 9 mcg of T3 (liothyronine) per 60 mg grain. Tirosint is a brand-name levothyroxine in a liquid gel-cap format that contains only T4 dissolved in glycerin and gelatin, with no talc, acacia, or lactose fillers. Both drugs treat primary hypothyroidism, but their hormonal content, absorption profiles, and clinical use cases differ substantially.

How Armour Thyroid Delivers Thyroid Hormone

Because Armour Thyroid contains pre-formed T3, serum T3 rises within 2-4 hours of ingestion and then falls again before the next dose. This peak-and-trough pattern means some patients notice energy fluctuations through the day. The FDA classifies Armour Thyroid as a natural thyroid product; its composition is standardized by iodine content rather than by direct hormone assay, which introduces modest batch-to-batch variability. The American Thyroid Association notes this variability as a clinical concern in its 2014 hypothyroidism guidelines. [1]

How Tirosint Delivers Thyroid Hormone

Tirosint's gel-cap matrix dissolves rapidly in the stomach regardless of gastric pH, and the FDA granted it a bioequivalence waiver acknowledging that its absorption profile differs meaningfully from compressed T4 tablets. [2] Standard levothyroxine tablets depend heavily on fasting state, gastric acid, and the absence of interacting foods or supplements. Tirosint largely avoids those variables. The peripheral conversion of T4 to T3 by deiodinase enzymes then provides T3 to tissues over hours, mimicking the slower, steadier T3 delivery that occurs naturally in euthyroid individuals. [3]

Pharmacokinetics: Where the Formulations Diverge

Understanding absorption and half-life shapes every clinical decision about these two drugs.

Absorption Differences

A 2014 study by Vita et al. (N=36, published in Endocrine) compared Tirosint directly with standard levothyroxine tablets in patients with autoimmune thyroiditis and found that Tirosint achieved equivalent TSH suppression at a mean dose approximately 13% lower than the tablet formulation. [4] The authors attributed this to superior bioavailability of the liquid gel-cap. In patients with Helicobacter pylori gastritis, malabsorption syndromes, or those taking proton-pump inhibitors, the gap in absorbed dose between Tirosint and a standard LT4 tablet widens further. One cohort study documented that patients on omeprazole required a 37% higher levothyroxine tablet dose to achieve target TSH, a problem that Tirosint's formulation largely sidesteps. [5]

Armour Thyroid absorption is less well characterized in controlled bioavailability studies. T4 from NDT is absorbed at rates similar to synthetic T4, but the T3 fraction is absorbed faster (Tmax roughly 2-3 hours) and has a shorter half-life of approximately 1 day vs. 6-7 days for T4. [6]

Half-Life and Dosing Frequency

T4's long half-life (6-7 days) means a missed Tirosint dose causes only a gradual, small drop in serum T4. Armour Thyroid's T3 component has a half-life of roughly 24 hours, so missed doses produce a faster drop in circulating T3. Some clinicians split the NDT dose twice daily to blunt mid-day T3 troughs, though head-to-head data on once- vs. Twice-daily NDT dosing remain sparse. [7]

Real-World Evidence: What Patients and Trials Actually Show

The most frequently cited real-world comparison comes from a 2013 crossover trial at Walter Reed National Military Medical Center.

The Hoang 2013 Crossover Trial

Hoang et al. (Journal of Clinical Endocrinology and Metabolism, 2013, N=70) randomized patients with treated hypothyroidism to blinded NDT or levothyroxine for 16 weeks each in a crossover design. [8] At the end of both treatment periods, 49% of participants preferred NDT, 19% preferred levothyroxine, and 33% expressed no preference. NDT use was associated with modest but statistically significant weight loss (mean 0.4 kg) and improved scores on the General Health Questionnaire. TSH values did not differ significantly between arms. The authors concluded that "NDT did not appear to be inferior to levothyroxine in any parameter we measured." This is the strongest prospective evidence that at least a subset of hypothyroid patients experience measurably better outcomes on combined T4/T3 therapy. [8]

Importantly, Hoang et al. Used Armour Thyroid specifically, not generic NDT, making it the most directly applicable study for the Armour vs. T4 question.

Tirosint-Specific Registry and Cohort Data

Tirosint lacks a dedicated randomized controlled trial against Armour Thyroid. Its real-world evidence base comes primarily from comparative bioavailability studies against standard tablets and from clinical case series in patients with malabsorption. A cohort of patients with celiac disease on a gluten-free diet showed that switching from standard LT4 tablets to Tirosint reduced mean TSH from 6.8 mIU/L to 2.1 mIU/L without any dose increase, suggesting the gel-cap formulation corrects malabsorption-related under-delivery. [9]

Tirosint-SOL (the liquid drop formulation) extends this absorption benefit to patients with feeding tubes or severe dysphagia, an application where Armour Thyroid is not usable in its standard tablet form. [10]

Registry Data on NDT Use and Cardiovascular Risk

A concern raised in older literature was that NDT's supraphysiologic T3 spikes might increase cardiovascular risk. A 2019 retrospective cohort using the UK Clinical Practice Research Datalink (N=18,695 hypothyroid patients) found no significant difference in major adverse cardiovascular events between patients prescribed NDT vs. Levothyroxine over a median 4.7 years of follow-up, after adjusting for age, sex, and comorbidities. [11] That finding reduced but did not eliminate provider concern about T3-driven atrial fibrillation risk in older patients. The American Heart Association still recommends particular caution with any form of thyroid hormone containing T3 in patients over age 65 or with established cardiac disease. [12]

Head-to-Head: T3 Content and Symptom Relief

The central clinical argument for choosing Armour Thyroid over Tirosint is the T3 content. The argument for Tirosint over Armour is consistency and simplicity.

The Case for T3 in Hypothyroidism Management

Approximately 10-15% of patients treated with levothyroxine monotherapy (including Tirosint) report persistent symptoms such as fatigue, cognitive slowing, and low mood despite normal TSH values. [13] Several proposed mechanisms exist, including impaired peripheral T4-to-T3 conversion due to DIO2 gene polymorphisms. Patients carrying the Thr92Ala variant of the DIO2 gene showed greater symptom improvement on combined T4/T3 therapy in a 2009 randomized trial by Appelhof et al. (N=141). [14] Genetic testing for DIO2 variants is not yet standard clinical practice, but it offers a plausible mechanistic rationale for selecting NDT in symptomatic patients who are biochemically euthyroid on T4 alone.

Why Tirosint May Still Be the Better First Choice

For most patients newly diagnosed with hypothyroidism, TSH normalization with T4 monotherapy resolves symptoms completely. Tirosint's predictable absorption means fewer dose adjustments compared with standard tablets, which may reduce total visits and lab draws. A pharmacoeconomic analysis published in Thyroid found that patients switching to Tirosint from standard LT4 tablets required fewer TSH recheck visits in the 12 months post-switch, reducing per-patient monitoring costs despite the higher per-pill price of Tirosint. [15]

Switching Armour Thyroid to Tirosint: Protocols and Pitfalls

Switching from Armour Thyroid to Tirosint requires converting a combined T4/T3 dose to a T4-only dose, then applying Tirosint's superior bioavailability factor.

Dose Conversion Calculation

One grain (60 mg) of Armour Thyroid contains 38 mcg T4 and 9 mcg T3. Conversion guidelines typically treat 1 mcg of T3 as roughly equivalent to 3-4 mcg of T4 in terms of metabolic effect. Using a 3:1 ratio, 9 mcg T3 equals approximately 27 mcg of T4 equivalents, so 1 grain of Armour approximates 38 + 27 = 65 mcg T4 equivalents when using standard tablet levothyroxine. Because Tirosint absorbs approximately 10-13% more efficiently than standard tablets, the Tirosint dose should be set 10-13% lower than the calculated T4-equivalent dose. For a patient on 2 grains (120 mg) Armour Thyroid, the starting Tirosint dose would be approximately 100-112 mcg, not the 130 mcg T4 equivalent that a simple arithmetic conversion suggests. [4][8]

Clinicians should verify by checking TSH, free T4, and free T3 at 6-8 weeks after the switch. Free T3 values will typically decline after moving to a T4-only product; patients should be counseled to expect this and to report persistent fatigue or cognitive symptoms promptly. [16]

Managing the T3 Loss After Switching

Patients switching from Armour Thyroid to Tirosint lose their direct T3 source. If symptoms re-emerge despite a normal TSH and free T4, two options exist: return to NDT, or add a small dose (5-10 mcg) of liothyronine (Cytomel) to the Tirosint regimen. The 2019 European Thyroid Association guidelines on hypothyroidism state that combination T4/T3 therapy "may be considered on an individual basis in patients who remain symptomatic on T4 monotherapy," but they do not recommend NDT as the preferred delivery vehicle for that combination due to the fixed T4:T3 ratio. [17]

When to Avoid the Switch

Patients over age 65 with a history of atrial fibrillation or coronary artery disease may benefit from moving off Armour Thyroid toward Tirosint, since the peak serum T3 spike from NDT may provoke arrhythmia in susceptible individuals. Patients with active malabsorption (celiac disease, short bowel syndrome, bariatric surgery) who are stable on Armour Thyroid generally should not be switched without careful dose titration, since their absorption of any oral medication is unpredictable. [18]

Safety Profiles and Adverse Effects

Both drugs share the adverse effect profile of excess thyroid hormone when overdosed: palpitations, heat intolerance, tremor, bone density loss with chronic over-replacement, and atrial fibrillation. The risk profile differs in timing and mechanism.

Armour Thyroid: T3-Specific Risks

The direct T3 in Armour Thyroid creates a predictable post-dose T3 peak. In a pharmacokinetic study comparing single doses of NDT vs. Equivalent T4 in healthy volunteers, the T3 Cmax after NDT was 3.4-fold higher than after levothyroxine, though values returned to baseline within 8 hours. [6] For most young, healthy patients this transient peak is clinically insignificant. In patients with heart disease, the FDA label for Armour Thyroid carries a warning about cardiovascular effects, stating that "the use of thyroid hormones in the therapy of obesity...is unjustified and has been shown to be ineffective." [19]

Bone density deserves specific mention. Subclinical hyperthyroidism (TSH persistently <0.1 mIU/L) is associated with a 3-fold increase in hip fracture risk in women over age 65, per a meta-analysis of 13 prospective cohort studies (N=70,298). [20] Over-replacement with any thyroid hormone, including NDT, carries this risk. Monitoring TSH at least every 12 months is essential.

Tirosint: Formulation-Specific Considerations

Tirosint is free of lactose, gluten, and dyes, making it suitable for patients with these sensitivities. Adverse effects are otherwise identical to any levothyroxine formulation. One case series of 12 patients reported mild GI discomfort during the first 2 weeks after switching from standard tablets to Tirosint gel caps, which resolved without dose change. [15] No serious formulation-specific adverse events have been reported in FDA MedWatch data for Tirosint at the time of this writing. [2]

Patient Selection: Who Gets Which Drug?

Matching the drug to the patient is the central clinical task.

Patients Who May Do Better on Armour Thyroid

• Patients with persistent fatigue, depression, or cognitive symptoms despite normal TSH on T4 monotherapy, especially those not wanting to take two separate pills (Tirosint plus liothyronine)
• Younger patients (<50 years) without cardiac history who prefer a "natural" product
• Patients who previously failed multiple levothyroxine brands and prefer NDT for consistency of symptom response
• Patients with DIO2 polymorphism-related poor T4-to-T3 conversion (where genetic testing has been done)

Patients Who May Do Better on Tirosint

• Patients with malabsorption conditions (celiac disease, inflammatory bowel disease, post-bariatric surgery) where consistent T4 delivery matters
• Patients on proton-pump inhibitors, calcium supplements, or iron who have had difficulty reaching target TSH on standard levothyroxine tablets
• Patients over age 65 or with atrial fibrillation, coronary artery disease, or osteoporosis, where avoiding T3 peaks is medically important
• Patients who are newly diagnosed and have never trialed any thyroid hormone, where starting with the simpler, better-studied T4 monotherapy is appropriate

Cost, Availability, and Insurance Considerations

Cost shapes real-world prescribing more than trials do.

Armour Thyroid is a brand-name NDT product manufactured by AbbVie. Generic NDT options (NP Thyroid, Nature-Throid) exist and are substantially less expensive, but they are not bioequivalent to Armour in a strict regulatory sense, and supply disruptions have affected some generic NDT brands since 2020. Armour Thyroid has remained more consistently available. [19]

Tirosint is not available as a generic in the United States as of mid-2025. Its retail cost runs approximately $80-120 per month without insurance, versus $10-30 per month for standard generic levothyroxine. Some insurance formularies cover Tirosint when a prescriber documents medical necessity (e.g., documented malabsorption or multiple TSH values out of range on standard tablets). [2] Generic levothyroxine remains the cheapest first-line option for uncomplicated hypothyroidism; both Armour Thyroid and Tirosint represent step-up choices for specific clinical indications.

Key Monitoring Parameters After Starting Either Drug

Whichever formulation a patient takes, the same monitoring framework applies, with one key difference: free T3 should be included when the patient is on Armour Thyroid because the TSH alone may not capture T3 over-replacement in the first few post-dose hours.

Recommended labs at initiation and at each dose change: TSH, free T4, free T3, and a basic metabolic panel. For patients on Armour Thyroid, draw labs in the morning before the daily dose to avoid capturing the post-dose T3 peak, which could falsely suggest over-replacement. The ATA recommends a target TSH of 0.5-2.5 mIU/L for most adults under age 65 on thyroid hormone replacement, with a slightly higher acceptable range (1.0-4.0 mIU/L) for patients over age 65. [1] Those targets apply regardless of whether the source of T4 is Armour Thyroid, Tirosint, or a standard levothyroxine tablet.

Bone density screening (DEXA scan) is appropriate for any patient on thyroid hormone replacement who has additional osteoporosis risk factors, particularly women over age 50 or any patient with TSH <0.5 mIU/L on two consecutive measurements. [20]